Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.

Wildes, Tanya M; Farrington, Laura; Yeung, Cecilia; Harrington, Alexandra M; Foyil, Kelley V; Liu, Jingxia; Kreisel, Friederike; Bartlett, Nancy L; Fenske, Timothy S

Wildes, Tanya M; Farrington, Laura; Yeung, Cecilia; Harrington, Alexandra M; Foyil, Kelley V; Liu, Jingxia; Kreisel, Friederike; Bartlett, Nancy L; Fenske, Timothy S.

Afiliação

Wildes TM; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA.
Farrington L; Division of Hematology and Oncology, East Tennessee State University College of Medicine, Johnson City, TN, USA.
Yeung C; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Harrington AM; Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
Foyil KV; Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.
Liu J; Division of Biostatistics, Washington University School of Medicine, St Louis, MO, USA.
Kreisel F; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Bartlett NL; Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.
Fenske TS; Medical College of Wisconsin, Division of Hematology & Oncology, Milwaukee, WI, USA.

Ther Adv Hematol ; 5(1): 3-12, 2014 Feb.

Article em En | MEDLINE | ID: mdl-24490019

Palavras-chave

Burkitt lymphoma; chemotherapy; rituximab; survival

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Hematol Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google